Dr Ferzaan N Engineer joins AUM Biosciences’ as Board Observer
AUM Biosciences (AUM), a Singapore-based biotech company officially announced today that Dr Ferzaan N Engineer has joined its Board. AUM is focused on the development of innovative and affordable oncology medicines for cancers with high unmet medical needs in Asia.
About Dr Ferzaan N Engineer
Dr Ferzaan N Engineer brings 30 years of clinical research and business leadership experience to AUM’s Board of Directors. In the past few years, Ferzaan co-founded three new ventures. He is Chairman of Cytecare Hospitals, a speciality cancer hospital, Co-Chairman of Medwell Ventures, a company offering home healthcare services under the Nightingales brand, and Director of Cytespace Research, a site management organisation.
A common thread that runs through Ferzaan’s career has been his desire to develop the pharmaceutical and healthcare industries in India. As Chairman & CEO of Quintiles India, he was instrumental in establishing India’s first international Clinical Research Organization (CRO). He was a member of the Asia-Pacific Management Board of Quintiles. He has also been appointed Distinguished Mentor at Escape Velocity Accelerator in Bangalore. Ferzaan currently serves as an Independent Director on the Board of Sun Pharma Advanced Research Company.
“This is an exciting period for cancer researchers. Advances in science are leading to breakthrough treatments for cancer patients that are targeted and have fewer side effects. AUM Biosciences has a unique drug development model which promises to positively contribute to the next generation of cancer drugs,” said Dr Ferzaan N Engineer, Board Member, AUM Biosciences.
In previous years, Ferzaan has served as Vice President of R&D at Core Healthcare Limited and has held advisory Board positions at Image Core Lab and Cellworks Group, Inc. He has also held advisory positions on the CII National Committee on Drugs and Pharmaceuticals, FICCI Pharmaceuticals and Biotechnology Committee and India Society of Clinical Research (ISCR). He is the recipient of the AACP New Investigator’s Award and has been a member of leading professional bodies such as the American Association of Pharmaceutical Scientists (AAPS) and American Association of Colleges of Pharmacy (AACP). Ferzaan has lectured at the University of Cambridge, Indian Institute of Management Ahmedabad and various global conferences. He has published over 30 research papers and abstracts in leading international journals.
“Ferzaan is an excellent addition to AUM’s Board, bringing to the team his entrepreneurial prowess and his highly sophisticated research strength. His contributions to the indian healthcare environment also makes him a valuable member of AUM’s Board,” said Vishal Doshi, CEO, AUM Biosciences
Ferzaan completed his Ph.D. in Pharmaceutical Sciences in 1990 at the University of South Carolina, following a Bachelor of Pharmacy (BPharm) degree from the L.M. College of Pharmacy. He has attended management training programs at the Indian Institute of Management Ahmedabad, INSEAD and the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill.
AUM Biosciences is an oncology-focused biotechnology company that aims to develop innovative, affordable cancer medicines. AUM Biosciences focuses on early-stage development of innovative medicines for the treatment of cancers. With a huge opportunity to identify targets for unmet medical needs, AUM Biosciences will partner and collaborate with leading research institutes, clinicians and pharmaceutical companies bringing new, affordable and effective therapies to patients in need.